[Comment] Addition of platinum salts to neoadjuvant chemotherapy in triple-negative breast cancer: a new standard of care?

The St Gallen Consensus Conference panel strongly endorsed the preference for neoadjuvant therapy in stage II and III triple-negative breast cancer.1 In The Lancet Oncology, Sibylle Loibl and colleagues report the results of the randomised, double-blind, phase 3, BrighTNess trial.2 The study assessed the addition of the poly(ADP-ribose) polymerase (PARP) inhibitor veliparib plus carboplatin, or carboplatin alone, to a standard neoadjuvant chemotherapy regimen (weekly paclitaxel followed by doxorubicin and cyclophosphamide) in patients with triple-negative breast cancer, and showed that the proportion of patients who achieved a pathological complete response significantly improved in the veliparib plus carboplatin plus paclitaxel group compared with the paclitaxel-based chemotherapy alone group (168 [53%] of 316 patients vs 49 [31%] of 158 patients, p

Source: The Lancet Oncology - February 28, 2018 Category: Cancer & Oncology Authors: Giuseppe Curigliano Tags: Comment Source Type: research